La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SomnoMed Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amrita Blickstead

Amministratore delegato

AU$91.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4yrs
Proprietà del CEO	0.5%
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18

Recent updates

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14

AMMINISTRATORE DELEGATO

Amrita Blickstead

4yrs

Mandato

AU$91,206

Compensazione

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Amrita Blickstead	Co-CEO & Executive Director	no data	AU$91.21k	0.49% A$ 416.3k
Karen Borg	Co-CEO & Executive Director	no data	AU$91.21k	0.22% A$ 185.7k
Mark Harding	Vice President of Global Marketing	5.1yrs	AU$505.38k	0.067% A$ 56.4k
Matthew Conlon	Executive VP of Sales & Marketing - North America	4.8yrs	AU$623.78k	0.039% A$ 33.1k
Marco Van Kleef	Vice President of Marketing & Sales - Europe	no data	AU$525.51k	Nessun dato
Darren Collins	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Terence Flitcroft	Company Secretary	29.6yrs	AU$10.56k	Nessun dato
Christopher Bedford	Vice President of Global Production and Product Development	no data	AU$195.00k	Nessun dato

5.0yrs

Durata media

Gestione esperta: Il team dirigenziale di SOM è considerato esperto (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Amrita Blickstead	Co-CEO & Executive Director	4yrs	AU$91.21k	0.49% A$ 416.3k
Karen Borg	Co-CEO & Executive Director	3.8yrs	AU$91.21k	0.22% A$ 185.7k
Michael Gordon	Non-Executive Director	4yrs	AU$92.34k	0.10% A$ 87.8k
Iven Klineberg	Member of the Medical Advisory Board	no data	Nessun dato	Nessun dato
J. Gerschman	Member of the Medical Advisory Board	no data	Nessun dato	Nessun dato
Peter Cistulli	Chairman of the Medical Advisory Board	no data	Nessun dato	Nessun dato
Gaetano Russo	Chairman of the Board	4yrs	AU$184.68k	0.64% A$ 542.2k
Hamish Corlett	Non-Executive Director	6.3yrs	AU$91.21k	Nessun dato

4.0yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SOM sono considerati esperti (durata media dell'incarico 4 anni).

SomnoMed Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Somnomed Limited Announces Executive Changes

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

Recent updates

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45

Full year earnings released - AU$0.0069 loss per share

New 90-day high: AU$2.14

Chairman of the Board recently bought AU$203k worth of stock

New 90-day high - AU$1.58

Full year earnings released

SomnoMed Limited to Report Fiscal Year 2020 Results on Aug 24, 2020

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

AMMINISTRATORE DELEGATO

Mandato

Compensazione